<DOC>
	<DOCNO>NCT00885378</DOCNO>
	<brief_summary>The purpose study compare reduction hemoglobin A1C ( A1C ) participant take saxagliptin combination metformin immediate release ( IR ) versus metformin IR alone .</brief_summary>
	<brief_title>Efficacy Safety Study Saxagliptin + Metformin Immediate Release ( IR ) Versus Metformin IR Alone Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes 1878 year age Taking stable twice daily ( BID ) dose metformin IR ( least 1500 mg ) least 8 week A1C : 710 % Cpeptide : ≥ 0.8 ng/mL Body mass index ( BMI ) : ≤45 kg/m^2 Women childbearing potential unable unwilling use acceptable birth control Women pregnant breastfeed Fasting plasma glucose ( FPG ) &gt; 270 mg/dL Significant cardiovascular history Symptoms poorly control diabetes History diabetic ketoacidosis hyperosmolar nonketotic coma Insulin therapy within one year screen Cardiovascular even within prior 6 month New York Heart Association Stage III/IV congestive heart failure and/or know leave ventricular ejection fraction &lt; =40 % Significant history renal hepatic disease History psychiatric disorder , alcohol drug abuse within previous year Treatment potent CYP3A4 inhibitor inducer Immunocompromised participant Active liver disease clinically significant abnormal hepatic , renal , endocrine , metabolic , hematological screening test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>